<p>Digital is disrupting pharmaceutical companies at their very core: product development and commercial operations.  We explore this with two leaders deep in the thick of transforming this key healthcare segment . . . 10% of the overall healthcare spend in the US . . . as digital innovation destroys and recreates the industry.</p>

Digital is disrupting pharmaceutical companies at their very core: product development and commercial operations. We explore this with two leaders deep in the thick of transforming this key healthcare segment . . . 10% of the overall healthcare spend in the US . . . as digital innovation destroys and recreates the industry.

<p>Digital is disrupting pharmaceutical companies at their very core: product development and commercial operations.&nbsp; We explore this with two leaders deep in the thick of transforming this key healthcare segment . . . 10% of the overall healthcare spend in the US . . . as digital innovation destroys and recreates the industry.</p>

Are pharmaceutical makers becoming outcomes companies? with AJ Ploszay, Ph.D. (GlaxoSmithKline) Brad Ansley (SPI Health)

We believe Mission and Margin is the business of healthcare.  

Business of Healthcare (BOH) interviews feature innovations sustainably improving healthcare Mission & Margin.  Each discussion includes a healthcare executive and innovator concentrating on the same problem.  Think “Nightline” or “How I Built This” just for healthcare.  

Recent guests have included Bernadette Spong, Chief Financial Officer, Orlando Health, Paul Kusserow, President & CEO, Amedisys, Blake Marggraff, Founder & Chief Executive Officer, Epharmix, and Charles Kolodkin, Chief Risk Officer, Cleveland Clinic.

The BOH audience of 19,000 senior executives from across healthcare . . . health system, payer, provider practice, government, pharma, device, health tech, and so on . . . access published interviews at www.BOHSeries.com.

Business

We believe Mission and Margin is the business of healthcare. Business of Healthcare (BOH) interviews feature innovations sustainably improving healthcare Mission & Margin. Each discussion includes a healthcare executive and innovator concentrating on the same problem. Think “Nightline” or “How I Built This” just for healthcare. Recent guests have included Bernadette Spong, Chief Financial Officer, Orlando Health, Paul Kusserow, President & CEO, Amedisys, Blake Marggraff, Founder & Chief Executive Officer, Epharmix, and Charles Kolodkin, Chief Risk Officer, Cleveland Clinic. The BOH audience of 19,000 senior executives from across healthcare . . . health system, payer, provider practice, government, pharma, device, health tech, and so on . . . access published interviews at www.BOHSeries.com.

We believe Mission and Margin is the business of healthcare.  

Business of Healthcare (BOH) interviews feature innovations sustainably improving healthcare Mission &amp; Margin.  Each discussion includes a healthcare executive and innovator concentrating on the same problem.  Think “Nightline” or “How I Built This” just for healthcare.  

Recent guests have included Bernadette Spong, Chief Financial Officer, Orlando Health, Paul Kusserow, President &amp; CEO, Amedisys, Blake Marggraff, Founder &amp; Chief Executive Officer, Epharmix, and Charles Kolodkin, Chief Risk Officer, Cleveland Clinic.

The BOH audience of 19,000 senior executives from across healthcare . . . health system, payer, provider practice, government, pharma, device, health tech, and so on . . . access published interviews at www.BOHSeries.com.

Share Are pharmaceutical makers becoming outcomes companies? with AJ Ploszay, Ph.D. (GlaxoSmithKline) Brad Ansley (SPI Health)

Sign up to save your podcasts

Are pharmaceutical makers becoming outcomes companies? with AJ Ploszay, Ph.D. (GlaxoSmithKline) Brad Ansley (SPI Health)

Are pharmaceutical makers becoming outcomes companies? with AJ Ploszay, Ph.D. (GlaxoSmithKline) Brad Ansley (SPI Health)